Table 1.
Characteristics of Patients and Expanded NK Cells for Clinical Trial
| Patient | Breed | Age | Sex | Weight (kg) | Injection #1a
(× 106) |
Viability (%) | Injection #2a
(× 106) |
Viability (%) |
|---|---|---|---|---|---|---|---|---|
| 1 | Black Lab | 14.8 | M | 29.6 | 30 | 79.3 | 0.3 | 1.0 |
| 2 | St. Bernard | 9.1 | M | 59 | 14.3 | 80.2 | 11.04 | 96.0 |
| 3 | Shepherd Mix | 9.1 | M | 23.8 | 392 | 98.9 | 155 | 100.0 |
| 4 | Shepherd Mix | 5.8 | M | 46 | 114.63 | 94.8 | 139.7 | 99.0 |
| 5 | St. Bernard | 1.2 | F | 57.6 | 75.93 | 98.6 | 26.7 | 97.2 |
| 6 | St. Bernard | 6.3 | M | 94 | 129.5 | 99.2 | 86.9 | 99.2 |
| 7 | Pyrenees | 7.5 | F | 57.1 | 139.5 | 95.0 | 94.5 | 96.0 |
| 8 | Doberman | 5.0 | M | 66 | 25 | 70.0 | 280 | 76.0 |
| 9 | Retriever Mix | 8.9 | F | 32 | 180 | 95.0 | 175 | 94.0 |
| 10 | Rhodesian Ridgeback | 10.2 | F | 35.1 | 115 | 95.0 | 17 | 95.0 |
aExpanded NK cells were documented to be LPS and Mycoplasma negative prior to adoptive transfer